Atreca, a US-based immune-focused medicine developer based on research at Stanford University, completed an oversubscribed $125m series C round today led by an undisclosed existing investor described as a healthcare-focused fund.
The round included Tavistock Group’s Boxer Capital unit, Wellington Management Company, Cormorant Asset Management, Aisling Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.
Atreca is developing drugs based on the responsiveness of the human body’s immune system. Its lead program is focused on cancer and its lead candidate, ATRC-101, is being developed to target breast, lung and colon tumours.
The company was co-founded by Lawrence Steinman, the George Zimmermann professor of neurology and neurological sciences and paediatrics in Stanford University’s School of Medicine.
John Orwin, Atreca’s president and chief executive, said: “This funding enables us to broaden and accelerate our discovery and pipeline generation efforts and to move our…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?